{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:47:03Z","timestamp":1772160423690,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical data on patients infected with influenza B Victoria (BV) after the approval of baloxavir is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational study of the Japanese 2023\u20132024 influenza season analyzed data from 25 outpatients with A(H1N1)pdm09, 36 with A(H3N2), and 65 with BV. Viral samples were collected before and after administering an antiviral (70 patients received baloxavir and 56 received a neuraminidase inhibitor), on days 1, 5, and 10. Isolated viruses after culturing were amplified using RT\u2010PCR and sequenced to detect mutations of concern, including acidic protein (PA)\u2010amino acid (AA) E23X\/I38X for influenza A and M34X\/I38X for BV. Fever and symptoms were tracked via self\u2010reporting diaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No PA\u2010AA\u2010substituted virus was detected from 126 pre\u2010treatment samples. In the baloxavir cohort, one (7.1%, 1\/14) PA I38F\u2010substituted A(H1N1)pdm09 and two (11.1%, 2\/18) PA I38T\u2010substituted A(H3N2) viruses were isolated on day 5 but not on day 10. No (0%, 0\/37) PA\u2010AA\u2010substituted BV was detected on day 5 or after. The virus isolation rate on day 5 was higher among patients with BV than with influenza A in both baloxavir (35.1% vs. 14.3% for A(H1N1)pdm09 and 16.7% for A(H3N2)) and oseltamivir\u2010treated patients (44.4% vs. 0% for A(H1N1)pdm09 and 33.3% for A(H3N2)). Patients with PA\u2010AA\u2010substituted influenza A after baloxavir administration did not have longer fever duration than those without virus isolation or with wild\u2010type virus on day 5, for both A(H1N1)pdm09 and A(H3N2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baloxavir\u2010resistant variants were not detected in influenza BV before treatment, as with A. The emergence of PA\u2010AA\u2010substituted influenza A after baloxavir administration was temporal and did not cause prolonged symptoms. No baloxavir\u2010resistant BV variants were observed after baloxavir administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/irv.70042","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T19:19:13Z","timestamp":1731957553000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023\u20132024 Season"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-9824","authenticated-orcid":false,"given":"Takeyuki","family":"Goto","sequence":"first","affiliation":[{"name":"Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine)  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Japan Physicians Association  Tokyo Japan"},{"name":"Kawai Clinic  Gifu Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Bando","sequence":"additional","affiliation":[{"name":"Japan Physicians Association  Tokyo Japan"},{"name":"Bando Clinic  Ishikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Takasaki","sequence":"additional","affiliation":[{"name":"Takasaki Pediatrics and Child Health Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Shindo","sequence":"additional","affiliation":[{"name":"Shindo Children's Clinic  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Sato","sequence":"additional","affiliation":[{"name":"Medicine and Biosystemic Science Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine)  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Fukuoka City Hospital  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rheumatology, and Infectious Disease Kyushu University Hospital  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[{"name":"Japan Physicians Association  Tokyo Japan"},{"name":"Ricerca Clinica co.  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Institute of Infectious Diseases. 2024.Weekly reports of influenza virus isolation\/detection accessed September 5 2024 https:\/\/kansen\u2010levelmap.mhlw.go.jp\/Byogentai\/Pdf\/data127e.pdf."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716197"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30004-9"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz908"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105092"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105853"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/505868"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.03.008"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.08.012"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.10.2990-2995.1998"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2014.04.016"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.08.013"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.06.003"},{"key":"e_1_2_9_16_1","unstructured":"National Institute of Infectious Diseases.Antiviral resistance surveillance in Japan accessed September 5 2024 https:\/\/www.niid.go.jp\/niid\/images\/flu\/resistance\/20240523\/dr23\u201024e20240523\u20101.pdf."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105281"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16934-1"},{"key":"e_1_2_9_19_1","unstructured":"World Health Organization.Summary of neuraminidase (NA) amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAIs) accessed September 5 2024 https:\/\/www.who.int\/publications\/m\/item\/summary\u2010of\u2010neuraminidase\u2010(na)\u2010amino\u2010acid\u2010substitutions\u2010associated\u2010with\u2010reduced\u2010inhibition\u2010by\u2010neuraminidase\u2010inhibitors\u2010(nais)."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.05.176"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105938"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T03:43:56Z","timestamp":1732592636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.70042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/irv.70042"],"URL":"https:\/\/doi.org\/10.1111\/irv.70042","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.70042\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.70042\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.70042\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.70042\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70042"}}